Amniotics AB (publ) (AMNI.ST)
SEK 0.01
(5.88%)
SEK 0.01
(5.88%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -29.09 Million | -46.18 Million | -15.63 Million | -61.77 Million | 562.95 Thousand | - |
| Net Income | -30.87 Million | -46.69 Million | -53.61 Million | -30.99 Million | -10.42 Thousand | -6859.16 |
| Depreciation & Amortization | 2.3 Million | 1.79 Million | 2.15 Million | 1.58 Million | 281.47 Thousand | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -2.31 Million | 170 Thousand | 35.9 Million | -32.42 Million | - | - |
| Other non-cash items | 6.39 Million | -1.45 Million | -79 Thousand | 60.7 Thousand | 10.42 Thousand | 6859.16 |
| Investing Cash Flow | -2.66 Million | -3.02 Million | -1.14 Million | -5.46 Million | - | - |
| Investments in PPE | -2.66 Million | -3.02 Million | -1.14 Million | -5.46 Million | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -2666.00 | -2159.00 | -1084.00 | -1000.00 | - | - |
| Financing Cash Flow | 30.86 Million | 14.33 Million | 60.24 Million | 61.72 Million | - | - |
| Debt repayment | -3.92 Million | -14.33 Million | -116 Thousand | -1.44 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 34.78 Million | - | 60.96 Million | 60.27 Million | - | - |
| Other Financing Activities | -3.92 Million | 28.67 Million | -599 Thousand | 1.44 Million | - | - |
| Accounts receivables | 2.55 Million | -4.18 Million | 37.82 Million | -38.47 Thousand | - | - |
| Accounts payables | -3.49 Million | 5.54 Million | -5.09 Million | - | - | - |
| Inventory | -534 Thousand | - | - | - | - | - |
| Other working capital | -2319.00 | -1.18 Million | 3.17 Million | -32.38 Million | - | - |
| Cash at beginning of period | 9.1 Million | 43.98 Million | 510 Thousand | 6.02 Million | 1.07 Million | - |
| Cash at end of period | 8.21 Million | 9.1 Million | 43.98 Million | 510 Thousand | 6.02 Million | - |
| Capital Expenditure | -2.66 Million | -3.02 Million | -1.14 Million | -5.46 Million | - | - |
| Effect of forex changes on cash | 891.1 Thousand | - | 1000.00 | 1000.00 | - | - |
| Net cash flow / Change in cash | -892 Thousand | -34.87 Million | 43.47 Million | -5.51 Million | 4.95 Million | - |
| Free Cash Flow | -31.75 Million | -49.21 Million | -16.77 Million | -67.23 Million | 562.95 Thousand | - |
| Breakdown | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -5.82 Million | -30.87 Million | -6.02 Million | -6.6 Million | -11.85 Million | -46.69 Million |
| Depreciation & Amortization | 471 Thousand | 2.3 Million | 471 Thousand | 502 Thousand | 486 Thousand | 1.79 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -1.99 Million | -2.31 Million | -719 Thousand | -32.78 Million | 33.17 Million | 170 Thousand |
| Other non-cash items | 3.09 Million | 6.39 Million | -677 Thousand | -233 Thousand | 1.32 Million | -1.45 Million |
| Investing Cash Flow | -994 Thousand | -2.66 Million | -287 Thousand | -593 Thousand | -792 Thousand | -3.02 Million |
| Investments in PPE | -100 Thousand | -2.66 Million | - | - | - | -3.02 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -894 Thousand | -2666.00 | -287 Thousand | -593 Thousand | -792 Thousand | -2159.00 |
| Financing Cash Flow | 10.8 Million | 30.86 Million | 5 Million | 5.22 Million | 9.82 Million | 14.33 Million |
| Debt repayment | - | -3.92 Million | - | - | - | -14.33 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 13.88 Million | 34.78 Million | - | 5.22 Million | 15.67 Million | - |
| Other Financing Activities | -3.07 Million | -3.92 Million | 5 Million | 5229.00 | -5.85 Million | 28.67 Million |
| Accounts receivables | 188 Thousand | 2.55 Million | - | - | - | -4.18 Million |
| Accounts payables | - | -3.49 Million | - | - | - | 5.54 Million |
| Inventory | -534 Thousand | -534 Thousand | - | - | - | - |
| Other working capital | 2.74 Million | -2319.00 | -719 Thousand | -32.78 Million | 33.17 Million | -1.18 Million |
| Cash at beginning of period | 3.59 Million | 9.1 Million | 5.83 Million | 40.3 Million | 9.1 Million | 43.98 Million |
| Cash at end of period | 8.21 Million | 8.21 Million | 3.59 Million | 5.83 Million | 40.3 Million | 9.1 Million |
| Capital Expenditure | -100 Thousand | -2.66 Million | - | - | - | -3.02 Million |
| Effect of forex changes on cash | -4.61 Million | 891.1 Thousand | - | - | -31.17 Million | - |
| Net cash flow / Change in cash | 4.61 Million | -892 Thousand | -2.23 Million | -34.47 Million | 31.2 Million | -34.87 Million |
| Free Cash Flow | -5.29 Million | -31.75 Million | -6.95 Million | -39.11 Million | 22.16 Million | -49.21 Million |
VTXPF
COPHF
BREB
ACCELERATE
FIHO12
OAMCF